+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Autism - Pipeline Review, H1 2020

  • ID: 4911664
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 177 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4D Pharma Plc
  • Cox Biosciences LLC
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Ovensa Inc
  • Scioto Biosciences Inc
  • MORE
Autism - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H1 2020, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Autism - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 1, 20, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4D Pharma Plc
  • Cox Biosciences LLC
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Ovensa Inc
  • Scioto Biosciences Inc
  • MORE
  • Introduction
  • Autism - Overview
  • Autism - Therapeutics Development
  • Autism - Therapeutics Assessment
  • Autism - Companies Involved in Therapeutics Development
  • Autism - Drug Profiles
  • Autism - Dormant Projects
  • Autism - Discontinued Products
  • Autism - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Autism, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Autism - Pipeline by 4D Pharma Plc, H1 2020
  • Autism - Pipeline by AgeneBio Inc, H1 2020
  • Autism - Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020
  • Autism - Pipeline by APeT Holding BV, H1 2020
  • Autism - Pipeline by AsiaBiome, H1 2020
  • Autism - Dormant Projects, H1 2020
  • Autism - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Autism - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Autism, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4D Pharma Plc
  • AgeneBio Inc
  • AgoneX Biopharmaceuticals Inc
  • APeT Holding BV
  • AsiaBiome
  • Blackthorn Therapeutics Inc
  • BrainStorm Cell Therapeutics Inc
  • Cennerv Pharma (S) Pte Ltd
  • Cox Biosciences LLC
  • Curemark LLC
  • Cytocom Inc
  • Epigen Biosciences Inc
  • F. Hoffmann-La Roche Ltd
  • GW Pharmaceuticals Plc
  • Immuron Ltd
  • Insys Therapeutics Inc
  • Intra-Cellular Therapies Inc
  • Johnson & Johnson
  • Neurochlore
  • Omeros Corp
  • OptiNose US Inc
  • Ovensa Inc
  • Panorama Research Inc
  • Park Active Molecules
  • RespireRx Pharmaceuticals Inc
  • Reviva Pharmaceuticals Inc
  • RogCon Inc
  • Rugen Therapeutics R&D (Shanghai) Co Ltd
  • Scioto Biosciences Inc
  • Sengenics International Pte Ltd
  • Sosei Heptares
  • Stem Cell Medicine Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Zelira Therapeutics Ltd
Note: Product cover images may vary from those shown
Adroll
adroll